Neurol. praxi. 2008;9(1):37-41

Antikonvulziva v terapii bolesti – mechanizmy účinku

MUDr. Jiří Mastík
Neurologická klinika LF MU a FN u sv. Anny, Brno

Některá antikonvulziva (antiepileptika) mají vedle své hlavní indikace dobrý efekt v léčbě chronické neuropatické bolesti a v léčbě bolestí hlavy. V léčbě neuropatické bolesti řadíme antikonvulziva mezi adjuvantní analgetika (koanalgetika). K nejúčinnějším z nich patří v léčbě bolestivé diabetické polyneuropatie, polyneuropatie jiné etiologie a postherpetické neuralgie gabapentin a pregabalin. Karbamazepin je dosud lékem 1. volby v léčbě neuralgie trojklaného nervu. Valproáty a topiramát se používají v profylaktické léčbě migrény. Mechanizmus účinku jednotlivých antikonvulziv je značně komplexní a většinou není dosud detailně objasněn.

Keywords: antikonvulziva, adjuvantní analgetika, neuropatická bolest, neuralgie, migréna

Published: March 15, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mastík J. Antikonvulziva v terapii bolesti – mechanizmy účinku. Neurol. praxi. 2008;9(1):37-41.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ambler Z. Farmakoterapie neuropatické bolesti. Farmakoterapie 2006; 3: 277-280.
    2. Ambler Z. Lyrica v léčbě periferní neuropatické bolesti - výsledky neintervenční studie u pacientů v ČR. Sympozium Pfizer, 21. český a slovenský neurologický sjezd, Praha 2007.
    3. Ambler Z. Neuropatická bolest a současné možnosti její farmakologické léčby. Bolest 3; 2000: 17-21.
    4. Ambler Z. Základní mechanismy neuropatické bolesti. Sympozium Pfizer, 21. český a slovenský neurologický sjezd, Praha 2007.
    5. Backonja M, Beydoun A, Edwards KR et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-1836. Go to original source... Go to PubMed...
    6. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997; 17: 93-100. Go to original source... Go to PubMed...
    7. Dolezil D, Mastik J, Kotas R, Novotna I. Efficacy of topiramate in prophylactic treatment of migraine: first open label, multicenter study in Czech Republic. Cephalalgia 2003; 7 (Suppl) A: 717.
    8. Hovorka J, Doležal T. Pregabalin. Farmakoterapie 2006; 3: 255-263.
    9. Cheshire W.P. Treatment of trigeminal neuralgia. CNS Drugs 1997; 7: 98-110. Go to original source... Go to PubMed...
    10. Kotas R. Profylaktická léčba migrény. Klin Farmakol Farm 2006; 20: 26-29.
    11. MacFarlane BV, Wright A, O´Callaghan J, Benson HAE. Chronic neuropathic pain and its control by drugs. Pharmacol Ther 1997; 75: 1-19. Go to original source... Go to PubMed...
    12. Mastík J, Novotná I, Štoplová J, Klajblová I, Rektor I. Valproát sodný v profylaktické léčbě migrény. Bolest 2001; 2: 78-82.
    13. Mathew N, Lucker C. Gabapentin in migraine prophylaxis: A preliminary open label study. Neurology 1996; 46: (Suppl) A 169. Go to PubMed...
    14. Mazanec R, Mastík J, Ševčík P. Gabapentin (Neurontin) v léčbě neuropatické bolesti různé etiologie. Neurol. pro Praxi 2004; 4: 195-197.
    15. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000; 101: 359-371. Go to original source... Go to PubMed...
    16. Opavský J. Terminologie bolesti. Bolest 1998; 1: 4-7.
    17. Pain Terms: A current list with definitions and notes on usage. In: Merskey H, Bogduk N. (eds): Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed., IASP Press, Seattle, 1994: 207-213.
    18. Rosenstock J, Tuchman M, LaMoreaux L et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a doubleblind, placebo-controlled trial. Pain 2004; 110(3): 628-638. Go to original source... Go to PubMed...
    19. Rowbotham M, Harden N, Stacey B et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-1842. Go to original source... Go to PubMed...
    20. Silberstein SD. Divalproex sodium in headache - literature review and clinical guidelines. Headache 1996; 36: 547-555. Go to original source... Go to PubMed...
    21. Silberstein SD, Neto W, Schmidt J et al. MIGR-001 study group. Topiramate in migraine prevention. Results of a large controlled trial. Arch Neurol 2004; 61: 490-495. Go to original source... Go to PubMed...
    22. Stensrud P, Sjaastad O. Clonazepam (Rivotril) in Migraine Prophylaxis. Headache 1979; 19: 333-334. Go to original source... Go to PubMed...
    23. Waberzinek G, Markova J, Mastik J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine attack. Journal of the Neurological Sciences 2005; 238: (Suppl. 1) A 492. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.